news semaglutide Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots Use of semaglutide linked to

Weight neutrality of DPP-IV inhibitors has been explained by increases in circulating GLP-1 concentrations being insufficient to facilitate centrally mediated satiety responses

Eli Lilly and Company ( LLY ) spent most of 2026 fighting a single bearish idea: that the government would squeeze GLP-1 pricing until the growth math stopped working

Crucially, the obesity paradox is likely heavily confounded by two factors: (1) whether weight loss is intentional, and (2) the use of the BMI metric, which poorly reflects the contribution of body composition towards body weight in older adults [15, 34]

Brand-name products like Ozempic and Wegovy come as pre-filled pens and don't require reconstitution